WeLeader Biomedical Co

WeLeader Biomedical Co Assets per Share

The Total Assets per Share of WeLeader Biomedical Co (7713.TWO) as of Oct 21, 2026 is 53.85 TWD. In the previous year, Total Assets per Share was 43.93 TWD — a change of 22.57% (higher).

Assets per Share

53.85TWD

YoY

22.57%

Last updated:

Total Assets per Share of WeLeader Biomedical Co is 2025 53.85 TWD. Total Assets per Share of WeLeader Biomedical Co was 2024 43.93 TWD. It decreases by 22.57% higher compared to the previous year.

The WeLeader Biomedical Co Assets per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Assets per Share
Date
Assets per Share
Jan 1, 2020
19.44 TWD
Jan 1, 2021
19.42 TWD
Jan 1, 2022
35.19 TWD
Jan 1, 2023
37.99 TWD
Jan 1, 2024
43.93 TWD
Jan 1, 2025
53.85 TWD
The WeLeader Biomedical Co Assets per Share history
YEARAssets per ShareYoY
53.85TWD+22.57%
43.93TWD+15.66%
37.99TWD+7.94%
35.19TWD+81.24%
19.42TWD-0.10%
19.44TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

WeLeader Biomedical Co Stock analysis

What does WeLeader Biomedical Co do? WeLeader Biomedical Co Ltd generates revenue through the agency and trading of in vitro diagnostic instruments and reagent-related products, primarily serving domestic markets. The company provides distribution, after-sales, and maintenance services for laboratory reagents, consumables, instruments, and equipment, alongside construction planning for medical testing laboratories. Additional services include equipment procurement, operational coaching, human resources training, and digital medical examination platforms. Domestic clients purchase these integrated solutions for healthcare facilities and laboratories. The firm's product portfolio focuses on medical testing-related services, including operational coaching and digital platform solutions, which are sold to healthcare institutions requiring comprehensive laboratory support. Distribution of in vitro diagnostic instruments and reagents forms a core revenue stream, supported by ancillary services like equipment procurement and site construction planning. These offerings target domestic healthcare providers seeking efficient laboratory management solutions. WeLeader Biomedical Co Ltd's business model combines product sales with service delivery, emphasizing domestic market penetration. The company's revenue is derived from both the sale of diagnostic instruments and reagents and the provision of specialized services such as operational coaching and digital platform access. Healthcare institutions and laboratories are the primary buyers of these integrated offerings, leveraging the company's expertise in laboratory construction and equipment maintenance. WeLeader Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about WeLeader Biomedical Co stock

Total Assets per Share of WeLeader Biomedical Co is 53.85 TWD in 2025.

Total Assets per Share of WeLeader Biomedical Co changed from 43.93 TWD to 53.85 TWD, representing a 22.57% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Assets per Share WeLeader Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

Assets per share divides total assets by shares outstanding, indicating the total resource base backing each share of stock.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — WeLeader Biomedical Co

All Key Metrics — WeLeader Biomedical Co